Key facts
- This page summarizes Mark K. White's Form 4 filing for Annovis Bio, Inc. (ANVS).
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 03 Jul 2024, 17:18.
Mark K. White - 17 Nov 2023 Form 4 Insider Report for Annovis Bio, Inc. (ANVS)
- Reporting relationship
- Director
- Issuer ticker
- ANVS
- Reported as of
- 17 Nov 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jul 2024, 17:18:10 UTC
- Prior SEC filing
- 11 Apr 2023
- Next SEC filing
- 22 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Maria Maccecchini Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark K. White filed Form 4 for Annovis Bio, Inc. (ANVS) on 03 Jul 2024.
Change
- Previous filing in this sequence was filed on 11 Apr 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ANVS
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +26,200
- Change %
- Price
- $0.000000
- Shares after
- 26,200
- Date
- 17 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 26,200
- Exercise price
- $6.07
- Footnotes
- F1, F2
ANVS
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +2,146
- Change %
- Price
- $0.000000
- Shares after
- 2,146
- Date
- 27 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,146
- Exercise price
- $7.39
- Footnotes
- F2, F3
ANVS
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +20,000
- Change %
- Price
- $0.000000
- Shares after
- 20,000
- Date
- 01 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,000
- Exercise price
- $5.27
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
On June 12, 2024, stockholders of Annovis Bio, Inc. ("the Company") approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved.
Footnote F2
The stock option shall vest immediately upon grant date.
Footnote F3
The stock option was granted in consideration for consulting services that reporting person will perform for the Company.
Footnote F4
The stock option shall vest in quarterly increments, based upon the services performed by the reporting person under the related Consulting Agreement.